川寧生物(301301.SZ):今年紅沒藥醇銷售目標在50噸左右
格隆匯8月6日丨川寧生物(301301.SZ)近日在接待機構投資者調研時表示,紅沒藥醇公司規劃年產能是300噸,目前已實現規模化生產,公司通過合成生物學技術生產的紅沒藥醇,達到了天然提取的品質,產品質量好,定價低於天然提取的紅沒藥醇價格,具有絕對成本競爭優勢。目前紅沒藥醇已形成銷售並貢獻部分收入,預計下半年紅沒藥醇銷量會有一定增長,今年紅沒藥醇銷售目標在50噸左右,具體的銷量還需根據市場情況而定。
上半年公司及經銷商共同努力開發推廣產品品牌,主要以國內銷售為主,下半年逐步拓展海外市場。因合成生物學產品處於產能爬坡期階段,開拓國際市場還需要一定的時間,除此之外,公司還會根據市場需求切換生產其他產品,加速產業化進程,儘快在合成生物學領域取得重要話語權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.